The DG75 Burkitt lymphoma-derived human B cell line is heterozygous for p53, carrying wild type (WT) and mutant (Arg283His) alleles. The cells constitutively express high levels of both p53 proteins and also Mdm2. Arg283His transactivates the p21 Waf1 , Mdm2, bax, cyclin G and IGF-BP3 promoters in transient transfection assays equally as well as, if not better than WT p53. It also suppresses the outgrowth of SAOS-2 cells and speci®cally binds DNA like wild type protein.
Introduction
Two major activities contribute to the tumour suppressor function of p53: in some cells p53 induces arrest in G 1 ± and sometimes G 2 /M ± of the cell division cycle, while in others it initiates death by apoptosis (reviewed in White, 1996; Levine, 1997) . Precisely what determines whether a particular cell should arrest or activate the suicide programme remains unclear. The molecular mechanism underlying the G 1 arrest mediated by p53 is largely the result of p53 transactivation of the Waf1 gene (El Deiry et al., 1993) which encodes the cyclin dependent kinase inhibitor known as p21 Cip1/Sdi/Waf1 . This protein is capable of blocking cell proliferation by both inhibiting the activity of the cyclin dependent kinases which are necessary for cell cycle progression (Dulic et al., 1994; reviewed in Sherr, 1996) and also directly inactivating the DNA replication machinery by binding to proliferating nuclear antigen (PCNA) and DNA polymerase d (Waga et al., 1994) . Another cyclin gene, encoding cyclin G, is also transactivated by p53 but the functional signi®cance of this remains to be determined (Okamoto and Beach, 1994; Zauberman et al., 1995) . Expression of the gene encoding the p53-binding protein Mdm2 is also activated by p53 (Barak et al., 1993; Wu et al., 1993) and it has recently been shown that Mdm2, through its physical association with p53, promotes the degradation of the latter in a proteosome-dependent manner and hence regulates its stability. It has been suggested that through this negative feedback loop the duration of the p53 response can be regulated (Wu et al., 1993; Haupt et al., 1997; Kubbutat et al., 1997) .
Sequence speci®c transactivation is also involved in the induction of apoptosis, but the molecular pathway(s) has yet to be determined. The most attractive candidate gene as a mediator of p53 induced cell death is Bax. Bax is a Bcl2-related protein which heterodimerises with Bcl2 and accelerates apoptosis (Oltavi et al., 1993) ; since the stoichiometry of Bcl2 ± Bax interactions determines whether cells survive or die following apoptotic stimuli, modulation of these genes by p53 could be an important component of p53-mediated apoptosis. However, although in some situations p53 can induce Bax expression (and reduce Bcl2 expression) (Miyashita et al., 1994; Zhan et al., 1994; reviewed in White, 1996) and p53 can activate the Bax promoter in transient assays (Miyashita and Reed, 1995) , increased Bax expression from genomic Bax genes is not always detected during p53-mediated apoptosis (Allday et al., 1995a , Canman et al., 1995 Rowan et al., 1996) . Furthermore in Bax-null`knockout' mice, p53-mediated apoptosis appears normal (Knudson et al., 1995) . Other genes which might, under certain circumstances, be activated by p53 include that encoding insulin-like growth factor binding protein-3 (IGF BP-3) which could potentially induce apoptosis by the paracrine blocking of a growth factor-generated survival signal (Buckbinder et al., 1995) .
p53-mediated apoptosis has also been reported in cells treated with the protein synthesis inhibitor cycloheximide (Caelles et al., 1994; Wagner et al., 1994) and some p53 mutants which cannot bind DNA or transactivate target genes can induce apoptosis in certain situations (Haupt et al., 1995; Chen et al., 1996) . The consensus of opinion is that a full apoptotic response requires both the amino and carboxyl termini of p53 and that these synergise in the activation of apoptosis by contributing both transcription-dependent and -independent functions Ko and Prives, 1996; Chen et al., 1996; Levine, 1997) .
Generally there is a good correlation between the ability of p53 protein to transactivate target promoters and suppress the growth of p53-null lines (Crook et al., 1994; Ory et al., 1994; Pietenpol et al., 1994) . However, several studies have dissociated transactivation from the ability of p53 to inhibit the transformation of primary rodent ®broblasts by combinations of cooperating oncogenes such as E1a or E7 and (Ha-)ras (Finlay et al., 1989; Eliyahu et al., 1989; Unger et al., 1993; Crook et al., 1994; Zhang et al., 1994) . Some transactivation competent mutants, such as Arg175Pro and Arg181Leu, have not only lost the ability to inhibit transformation but have gained modest transforming activity when transfected alone with ras.
More recently it has become apparent that while the activity of p53 mutants in transformation assays does not correlate well with transactivation, in some cases the ability to transform positively correlates with impaired apoptotic function (Rowan et al., 1996) . Further analysis has revealed that this loss of apoptotic activity may result from the inability of some mutants to activate speci®c cellular promoters. For example the transforming, transactivating mutant, Arg175Pro fails to transactivate the Bax and IGF BP-3 promoters or induce apoptosi . These data suggest the cellular response to a mutant p53 protein may depend on which p53-responsive genes it is capable of transactivating; however, the critical genes involved in apoptosis have yet to be identi®ed.
In rat embryo ®broblast (REF) clones transformed with mutant p53 and ras, co-precipitation of the transfected mutant protein and endogenous wild type rat p53 has been demonstrated (Eliyahu et al., 1988; Rovinski and Benchimol, 1988) ; this is consistent with the hypothesis that the protein encoded by the transfected, transforming mutant acts in a dominant negative manner and inactivates the endogenous rat protein. However, while this may sometimes be the case, at least two studies have shown that p53 mutants can have transforming activity in the absence of endogenous wild type protein (Dittmer et al., 1993; Sun et al., 1993) . This suggests that it may be possible for p53 to gain an additional oncogenic function independently of any dominant negative activity.
Burkitt lymphoma (BL)-derived cell lines all have a chromosomal translocation which leads to the deregulation of the c-myc proto-oncogene (reviewed in Lenoir and Bornkamm, 1987) . In addition a high proportion of cell lines examined have deletions and/or missense mutations of p53 (Farrell et al.,1991; Duthu et al., 1992; O'Connor et al., 1993; Allday et al., 1995b) . From various studies of primary tumour material, it appears that 20 ± 30% of BL carry p53 mutations in vivo (Giadano et al., 1991; Edwards and Raab Traub, 1994) . These observations are therefore consistent with mutations of p53 contributing to the oncogenic progression of a signi®cant proportion of BL. Although loss of heterozygosity occurs in many BL, various reports suggest that there is retention of the wild type allele in a range of B cell lymphoma (Edwards and Raab Traub, 1994; Allday et al., 1995b) . So ± unlike most other human tumours in which wild type alleles are rarely seen (Nigro et al., 1989; Takahashi et al., 1989; Slingerland et al., 1993) ± in some lymphoma (including BL), p53 mutants may transdominantly inactivate the wild type protein and consequently contribute to tumour progression.
Here we describe the characterization of the EBVnegative BL cell line DG75. This has revealed a novel, trans-dominantly acting, transforming p53 mutant which has a very unusual phenotype and which may prove useful in the analysis of the nuclear/cytoplasmic shuttling of p53.
Results
DG75 cells express wild type and mutant p53 (Arg283His), a low level of p21
Waf1 but a high level of mdm2 DG75 cells are remarkably resistant to DNA-damaging drugs such as cisplatin and adriamycin; they neither arrest in G1 nor undergo apoptosis (Allday et al., 1995b) ; it was therefore of interest to determine what, if any, p53 protein they express. Western blot analysis showed that they constitutively express an extremely high level of p53 (Figure 1a) , this is consistent with the presence of a mutant allele since in all the BL cell lines investigated we have never seen high levels of protein without a mutant allele. This is in contrast to proliferating primary human B cells and a lympho- (Figure 1a and also Figures 3b and 13b ). Further analysis of the p53 extracted from DG75 by separation in a lower percentage SDS-polyacrylamide gel showed a protein doublet (Figure 1b ). While this need not result from both alleles being expressed, it suggested that DG75 might be similar to Raji in this respect (Allday et al., 1995b) . Subsequent sequence analysis of p53 cDNA from DG75 revealed that in addition to mRNA corresponding to a wild type allele a missense mutation was detected in the second allele. This results in the substitution of an arginine residue at amino acid position 283 by histidine (Figure 2 ) (this is in agreement with results from another laboratory; K Wiman, personal communication). Further sequence analysis failed to reveal any other mutations.
If the p53 in these cells were transcriptionally active, there are a number of target genes which would be expected to be induced; these include p21
Waf1
, Mdm2 and Bax. The level of mRNA corresponding to p21
Waf1 was determined by Northern blotting to be extremely low and, in contrast to the LCL, was not induced after 8 h treatment with cisplatin ( Figure 3a) . This is consistent with the p53 in DG75 being unable to either transcriptionally transactivate the p21 Waf1 gene or respond to DNA damage. Stripping and reprobing ®lters showed that GADD45 mRNA expression was similarly unaected (data not shown). In contrast, a Western blot probed with the antiMdm2 speci®c monoclonal antibody SMP-14 (Picksley et al., 1994) revealed that DG75 cells constitutively express a signi®cantly higher level of Mdm2 than the X50-7 LCL, even after the latter was treated with cisplatin ( Figure 3b) . However, when a Southern blot was performed it was obvious this high level of Mdm2 did not result from gene ampli®cation and furthermore, Northern blotting showed the steady state level of Mdm2 speci®c mRNA to be similar in DG75 to in various B cell lines, including X50-7 (Figure 4a and b). This suggests that the high level of protein detected results from some post-transcriptional activity and could be due to the enhanced translation which has been reported in other human tumours (Landers et al., 1994) . It is currently unclear why there is an increase in Mdm2 protein after cisplatin treatment (Figure 3b ), since Northern blotting showed no increase in transcription (data not shown). Bax, a gene which under certain circumstances can also be induced by high levels of p53, is not expressed at a detectable level in DG75 cells in the presence or absence of cisplatin (see Figure 1a) . This is the result of a frameshift mutation in Bax exon 3 producing premature termination of translation (Brimmell M, Mendiola R and Packham G ± manuscript submitted for publication). It should also be noted that our previous report that DG75 expresses Bax (Allday et al., 1995b) was based on immunoblots using a commercial polyclonal antibody (P-19, Santa Cruz) which it was subsequently discovered recognizes a 23 kD protein but does not recognize human Bax (our unpublished observations and G Packham, personal communication). Since the analysis of gene expression in DG75 cells was consistent with all of the endogenous p53 being functionally inactive, the Arg283His mutation was engineered by site directed mutagenesis into p53 expression plasmids for further analysis. The DNA binding activity of Arg283His was determined using oligonucleotides including the p53 binding site(s) from the p21 Waf1 promoter. p53 genes corresponding to wild type, a transforming mutant (Tyr234His) (Parker et al., 1996) and the Arg283His mutant were transcribed and translated in vitro and analysed in electromobility shift assays (EMSAs). In the presence of the activating monoclonal antibody PAb421, wild type protein and Arg283His proteins bound the p21 oligonucleotide with similar eciency and this activity was abolished by the addition of excess, unlabelled competitor oligonucleotides ( Figure 5a ). Under the same binding conditions (in the presence of PAb421) the Tyr234His mutant failed to bind the probe. The equivalent translation of all three proteins was con®rmed by labelling with 35 Smethionine and SDS ± polyacrylamide gel electrophoresis ( Figure 5b) .
Next, the sequence speci®c transactivation activity of Arg283His was tested and compared with that of wild type p53 on a series of responsive promoters: Mdm2, p21
, Bax, cyclin G and IGF BP-3. This was done using the p53-null human tumour cell line SAOS-2 in transient transfection assays. The results from two representative experiments (Table 1) showed that, using 500 ng of eector DNA, the Arg283His protein is slightly more ecient at transactivating most promoters. The exception was Bax, which in these two experiments was activated slightly less by Arg283His. A further series of experiments were performed using 2 mg or 50 ng of eector DNA and the same target reporters. Since there is always considerable variation in transfection eciencies between experiments it is convenient to express activation relative to wild type so that the mean and standard deviation values can be calculated. Values from four experiments are illustrated graphically in Figure 6 . It is clear that at high concentrations Arg283His transactivates all the target promoters more eciently than wild type protein, but when only 50 ng of DNA were used the activitites of mutant and wild type protein were largely indistinguishable. They were equivalent down to 10 ng of pCB6 + expression plasmid ± the lowest level tested (data not shown). Although it is not really clear why the mutant is more eective than wild type at high concentrations of input DNA, this result is highly reproducible and could re¯ect dierences in protein stability in the nucleus. The expression of both proteins in whole cell extracts was judged by Western blotting to be equal (data not shown and for example, Figure 9b ).
Wild type p53 eciently suppresses the growth of p53-null tumour cell lines such as SAOS-2 and the study of various naturally occurring mutants has shown that there is generally a good correlation between transactivation by p53 and this suppression of cell growth (see Introduction). In order to determine whether this correlation holds true for Arg283His, parallel co-transfections of SAOS-2 cells with pCB6 35 S-methionine and separated on an SDS-10% polyacrylamide gel. Two p53 bands are generally seen when in vitro translated p53 is run through an SDS-10% polyacrylamide gel. The lower band is assumed to be the product of translational initiation from an internal methionine residue b Activation relative to luciferase activity produced in control vector transfected cells weeks after selection with G418 shows unequivocally that Arg283His suppresses the outgrowth of drug resistant colonies about as eciently as wild type p53 (Figure 7a ). The experiment was repeated with dierent batches of plasmid DNA and dierent amounts of p53 expression vectors and the results of a typical experiment are shown graphically in Figure 7b . The growth suppression induced by expression of Arg283His correlates well with its ability to transactivate p53 responsive promoters. The Tyr234His protein had no signi®cant eect on colony formation in similar assays (data not shown).
Arg283His fails to repress the oncogenic transformation of primary rodent ®broblasts
Human wild type p53 has been shown to inhibit the oncogenic transformation of early passage rat embryo ®broblasts (REFs) by human papillomavirus type-16 (HPV-16) E7 and ras genes (Crook et al., , 1994 . Many human tumour-derived missense mutant p53 alleles have lost this ability and some can even cooperate with ras alone to induce immortalization and transformation of REFs. Cotransformation assays were therefore performed with (Ha-)ras and HPV-16 E7; whilc wild type p53 inhibited the number of transformed, G418-resistant colonies produced, neither Tyr234His nor Arg283His had any repressive activity. Figure 8a shows the mean and standard deviation values from three separate experiments. Further transfections were performed in which p53 expression vectors were introduced into REFs with only (Ha-)ras (Figure 8b ). The mean of three experiments clearly shows that Arg283His has a moderate level of transforming activity, similar to that of Tyr234His and the well characterized mutant Arg273His (Slingerland et al., 1993; Crook et al., 1994) . Three clones from these experiments (two ras+283 and one ras+E7+283) were expanded and Western blot analysis performed using the human p53-speci®c mAb DO1; this showed the human protein is expressed in all three clones (Figure 8d ).
Transient expression of Arg283His induces apoptosis in SAOS-2 cells
There have been several reports of p53 mutants which are defective for suppression of transformation in rodent cells but which retain the ability to suppress the growth of p53-null human cells (see Introduction). In the case of at least one such mutant this is accompanied by a loss of apoptotic function in transient assays (Rowan et al., 1996) ; the ability of Arg283His to induce apoptosis in SAOS-2 cells was therefore investigated. Sixty hours after transfection with either vector (pCB6 + ) alone, wild type p53, Arg283His, or the two transforming mutants Arg273His or Tyr234His, cells were ®xed, stained for DNA content with propidium iodide and p53 expression with the monoclonal antibody DO1. The cell cycle pro®le for the transfected, p53-expressing cells was determined by¯ow cytometry. A typical experiment (Figure 9a) shows that both wild type and Arg283His induce a signi®cant increase in the sub-G1 population in the transfected cells (shown as M1 in Figure 9a ). This population represents the cells which are undergoing or have undergone apoptosis. In contrast, the transforming but transcriptionally inactive mutants Arg273His and Tyr234His fail to signi®cantly induce apoptosis. The analyses of ®ve more similar experiments are summarized in Table 2 . They consistently showed that Arg283His induces apoptosis with just over 50% the eciency of wild Arg283His is not retained in the cell nucleus and sequesters wild type p53 to the cytoplasm It is well established that some missense mutants of p53 which retain transcriptional activity fail to repress transformation of primary rodent cells. In some cases this may be because they are selectively defective in their ability to transactivate cell promoters. For instance Arg181Leu fails to activate the IGF BP-3 promoter and Arg175Pro fails to activate this or the bax promoter. It has been suggested that this dierential activation of cellular promoters may be responsible for the impairment of apoptotic function and the transforming activity of these mutants (Rowan et al., 1996; Ludwig et al., 1996; Friedlander et al., 1996) . Since we were unable to show a similar de®ciency in Arg283His and because the expression of some transforming mutants has been shown to be restricted to the cytoplasm (Diller et al., 1990; Martinez, 1991; Gannon and Lane, 1991; Slingerland et al., 1993) , this suggested to us an alternative mechanism whereby Arg283His might have gained transforming activity. Transformed REF clones were therefore analysed by immuno¯uorescence using the human p53-speci®c monoclonal antibody DO1. It is clear that the Arg283His protein in these cells is distributed largely in the cytoplasm (see for example, Figure 10a ). It was possible therefore, that Arg238His might act in a dominant negative manner by sequestering in the cytoplasm (and hence inactivating) the endogenous rat p53. To test this hypothesis, the transformed clones were stained using the monoclonal antibody PAb242, which recognizes rodent p53 but not human (Yewdell et al., 1986) . The staining pattern with this reagent is indistinguishable from that with DO1, suggesting that the endogenous p53 and transforming mutant may heterodimerize and co-localize in the cytoplasm (compare Figure 10a and b) . Treatment with the DNA damaging drug cisplatin for 8 h had no eect on the p53 staining pattern in these cells. It should be noted that cells transformed with Tyr234His gave distinct nuclear staining with mAb DO1 but that primary REFs stained with either DO1 or 242 produced no speci®c¯uorescence staining above the background level (data not shown).
Although it might explain the transforming activity of Arg283His, initially, the above results seemed rather counter-intuitive since we had previously showed that this mutant could eciently transactivate Cells were harvested and proteins were extracted 60 h after transfection. Track 1, Raji BL and track 2, DG75 control cells; track 3, no extract; tracks 4 ± 10, SAOS-2 cells; track 4, untransfected; track 5, mock-transfected; track 6, transfected with empty vector; track 7, Arg273His; track 8, Tyr234His; track 9, Arg283His; track 10, wild type p53. It should be noted that there was some spill-over of sample from track 7 to track 6 Representative results are shown in Figure 11 . Wild type p53 staining was almost entirely located in the nucleus of the transfected cells whether they were analysed at 24, 48 or 60 h post-transfection ( Figure  11a, b and c) . In contrast, the Arg283His mutant could be seen in both nucleus and cytoplasm at 24 h but by 48 h it was largely cytoplasmic with evidence of perinuclear accumulation in many cells (Figure 11d and e). At 60 h the mutant had a diuse, cytoplasmic distribution in most cells (Figure 11f ). Since the transient transactivation assays were routinely performed after 24 ± 30 h these data are consistent with Arg283His activating transcription from reporter plasmids by direct DNA binding in the nucleus of the SAOS-2 cells before it was expelled into the cytoplasm. It should be noted that after 60 h small, condensed, brightly staining cells could be seen (particularly in the population transfected with wild type p53), we assume these are cells which have undergone apoptosis but which have remained attached to the plastic substrate.
Transactivation of target promoters by Arg283His declines 24 ± 96 h after transfection
The immuno¯uorescence staining had shown that after transfection of SAOS-2 cells with pCB6 + Arg283His, there was a gradual reduction of nuclear ± and concomitant increase in cytoplasmic ± Arg283His protein over the next 4 days (Figure 11 and unpublished observations). If transactivation requires DNA binding in the nucleus, one would predict a reduction in transactivation by Arg283His (relative to wild type p53) during the same period of time. This was tested by transfecting SAOS-2 cells with wild type p53, another transactivating mutant (Arg175Pro, which transactivates p21
Waf1 but fails to induce apoptosis) or Arg283His together with the p21 Waf1 -luciferase reporter. Cells were harvested 1, 2, 3 and 4 days after transfection. The results, corrected for transfection eciency and cell survival, clearly showed that at the same time as Arg283His becomes excluded from the nucleus (Figure 11 ) so its ability to transactivate also declines (Figure 12 ). In contrast, activation by wild type and Arg175Pro continued to increase with time and is consistent with the general increase in intensity of nuclear staining seen in Figure 11 . These trends continued for up to 6 days post-transfection and similar results were obtained using the Mdm2-luciferase reporter (data not shown).
No p53 accumulates in the nucleus of DG75 cells after treatment with cisplatin
Finally, we returned to the DG75 cell line in order to determine the location of p53 protein and how it responds spatially to the genotoxic stress created by cisplatin. The BL2 cell line was used as a control since it is a Burkitt lymphoma-derived line which expresses two wild type p53 alleles (Farrell et al., 1991; Allday et al., 1995a, b) . The response of these cells to treatment with cisplatin (10 mg/ml) for 8 h was monitored by 24 h 48 h 60 h Figure 11 Transiently expressed Arg283His appears to be expelled from the nucleus. SAOS-2 cells were transfected with either pCB6 + WTp53: (a, b and c) or pCB6 + Arg283His: (d, e and f). At the times after transfection indicated under the panels, cells were ®xed and stained for immuno¯uorescence using the mAb DO1 immuno¯uorescence (Figure 13a ) and also Western blotting ( Figure 13b) ; PAb421 (Harlow et al., 1981) was used for immuno¯uorescence staining and the Western blot was sequentially probed with PAb421, DO1 and, as a loading control, anti-Bcl2. The level of p53 protein in BL2 cells dramatically increased with cisplatin treatment and this accumulated largely in the nuclei of the cells (Figure 13a and b) . In contrast, the high levels of p53 revealed on the Western blots of DG75 appears to be almost entirely excluded from the nucleus, both in the absence and presence of cisplatin. As in the transformed REFs, Arg283His was prevented from entering the nucleus after treatment with cisplatin; the wild type protein in DG75 appeared to be similarly compromised. The IF experiments were repeated using the mAb DO1 and, despite less intensē uorescent staining ± particularly in DG75 ± the results were essentially similar (data not shown).
Discussion

Arg283His binds DNA and transactivates target promoters
The type of genetic change in p53 most commonly occurring in cancer cells is a missense mutation in one allele which leads to the synthesis of a hyperstable, functionally defective protein. This is generally accompanied by a loss of the other allele (Levine, 1997 ). There appears to be strong selection for mutations localizing in the DNA binding domain ± aa102 ± 292 ± particularly in the conserved boxes II, III, IV and V . Most of these mutations alter the structural integrity of this domain or directly alter DNA contact sites; the resulting mutants are therefore generally defective for transactivation of p53-dependent target genes (Cho et al., 1994) . The Arg283His mutation found in the DG75 cell line maps within this DNA binding domain, in conserved box V and Arg283 normally forms part of the H2 ahelix (residues 278 ± 286) and makes contact with the phosphate backbone (guanine-7) in the major groove of the consensus DNA sequence (Cho et al., 1994) . There have been relatively few reports (n=6) of mutations to residue 283 and in only a single other case was arginine replaced by histidine (Hollstein et al., 1994; Cho et al., 1994) .
However, unlike most mutations in DNA-contacting residues, Arg283His still speci®cally binds DNA ( Figure 5 ) and consequently it can transactivate a wide range of p53 inducible promoters (Figure 6 ). We assume, therefore, that this mutation does not create major structural/conformational changes since the H2 a-helix must still ®t into the major groove to permit binding to the consensus sequence.
Transactivation, induction of apoptosis and suppression of transformation are apparently separable functions of p53
Based on the analysis of its sequence speci®c DNA binding activity, the analysis of transactivation using Figure 13 p53 in DG75 remain cytoplasmic even after DNA damage. (a) Cytospin preparation of BL2 and DG75 cells were ®xed and then stained by immuno¯uorescence using the anti-p53 mAb 421. While the nuclear staining of BL2 is obvious the apparent cytoplasmic' staining of these cells without drug treatment might only be background staining. (b) Protein extracts from the same cultures (*10 6 cells per track) were separated on an SDS 10%-polyacrylamide gel, transferred to nitrocellulose and also probed using mAb 421, the ®lter was stripped and reprobed with mAb DO1 and also anti-Bcl2 (Dako) ®ve dierent responsive promoters in transient transfection assays, its ability to suppress a SAOS-2 growth and the¯ow cytometric analysis of apoptotic function, Arg283His is largely indistinguishable from wild type p53 ± it appeared to be a functionally silent mutation or polymorphism. However, the high level of protein in the DG75 cells from which it was derived suggests it is a mutant. In addition, when its tumour suppressor activity was assessed in REFs transfected with cooperating oncogenes (HPV16 E7 and (Ha-ras)) it failed to suppress transformation and even showed modest transforming activity alone with Ha(-ras) (Figure 8 ). Thus Arg283His was established as a bona ®de oncogenic mutation. Insight into the nature of the transforming activity exhibited by Arg283His came when the transformed REFs were stained by IF for p53. The ectopic transforming human protein and also the endogenous rat p53 were both shown to be exclusively located in the cytoplasm. This is consistent with the mutant protein acting as a dominant negative molecule by sequestering the endogenous wild type p53 in the cytoplasm and preventing nuclear entry, even after DNA damage (Figure 10b and 13a) . Immunouorescence staining of Arg283His expressed transiently in SAOS-2 provided con®rmation that this mutant accumulates in the cytoplasm. Furthermore, these experiments explained how a cytoplasmic p53 can transactivate target reporters. Staining the cells early after transfection (*24 h) clearly showed a signi®cant amount of p53 localized to the nucleus (Figure 11d ) and since the initial series of transactivation assays were performed 24 ± 30 h post-transfection ( Figure 6 ) plenty of Arg283His would have been available for direct DNA binding and transactivation. It was only 48 ± 60 h after transfection that most of the mutant appeared to be expelled from the nucleus and accumulate in the cytoplasm and transactivation declined relative to the activity of wild type p53 (Figure 12 ). Since the nuclear localization signals in p53 are located at amino acids 316 ± 322 (NLS I) 369 ± 375 (NLS II) and 379 ± 384 (NLS III) (Dang and Lee, 1989; Shaulsky et al., 1990b) , there is no reason to believe the Arg283His mutation should directly in¯uence their activity. Deletion of these signals produces a protein which fails to enter the nucleus after transient transfection (see for example, Shaulsky et al., 1990) so the transient expression of Arg283His in the nucleus *24 ± 48 h after transfection is consistent with normal nuclear import signals operating.
Nuclear-cytoplasmic shuttling of p53 in normal and tumour-derived cells Cytoplasmic localization of p53 has been reported in various human tumours including in¯ammatory breast carcinoma, (Horack et al., 1991; Moll et al., 1992) , neuroblastoma (Moll et al., 1996; Goldman et al., 1996) , colorectal cancer, (Flamini et al., 1996) and ovarian cancer (Runnenbaum et al., 1996) and also the murine, temperature sensitive mutant p53
Val135 resides in the cytoplasm at 37 ± 39.58C (Martinez et al., 1991) . These data are all consistent with the widely held view that nuclear location is required for tumour suppressor activity. The mechanism underlying this aberrant subcellular distribution of p53 is, however, generally obscure. In in¯ammatory breast carcinoma and undifferentiated neuroblastoma, the p53 has been reported as wild type protein which is abnormally sequestered in the cytoplasm and hence epigenetically inactivated (Moll et al., 1992 (Moll et al., , 1996 . However, it is controversial whether this cytoplasmic localization in neuroblastoma has a significant eect on p53 signal transduction, since functional protein can be induced in the nucleus of these cells by ionising radiation (Goldman et al., 1996; Moll et al., 1996) . Results such as these raise the question of whether in some normal cell types, cytoplasmic distribution of p53 predominates. It has been suggested that in mouse ®broblasts the normal distribution may be cytoplasmic (Rotter et al., 1983) and that redistribution occurs at dierent times in the cell cycle (Shaulsky et al., 1990a ) also cytoplasmic p53 was demonstrated in normal human breast epithelial cells, foreskin keratinocytes and skin ®broblasts and again the proliferative state of the cells appeared to determine the distribution of p53 (Moll et al., 1992; Takahashi and Suzuki, 1994) . While it remains to be determined how universal and biologically relevant these phenomena are, it may be signi®cant that microinjected p53 can readily shuttle between the nucleus and cytoplasm (Middeler et al., 1997) .
Arg283His is an unusual p53 mutant which appears to be wild type in all but its ability to stay in the nucleus. We propose that this mutation may exaggerate a normal feature of p53 biology by facilitating abnormal binding to either a nuclear export protein or a cytoplasmic anchor (or both) and as such it should prove a valuable tool for probing the normal spatial regulation of p53. For reasons outlined above, we think it is unlikely Arg283His has undegone a major conformational change, but we cannot exclude the possibility that it becomes associated with one of the heat shock proteins such as hsp70 or 84 or some other chaperone in a conformational-dependent manner (Martinez et al., 1991; Gannon and Lane, 1991; Sepehrnia et al., 1996) . We favour the view that it is either aberrantly exported from the nucleus because of an enhanced interaction with a speci®c nuclear export protein or that it shuttles by some normal mechanism and is sequestered by abnormal anity to a cytoplasmic anchor. Since early after transfection into SAOS-2 there are many cells with exclusively nuclear staining (see for example Figure 11d ) the former model seems slightly more attractive. Whatever the mechanism all the data are consistent with Arg283His heterodimerizing with, and acting as a chaperone for, any wild type p53 protein in the cell. A detailed analysis of the proteins speci®cally interacting with Arg283His is currently in progress and should hopefully extend our understanding of how p53 function is regulated by intracell tracking.
Materials and methods
Cell lines and culture
B cell lines were maintained in RPMI medium with 10% fetal calf serum (FCS). Adherent cells were maintained in DMEM supplemented with 10% FCS. Primary Fisher rat embryo ®broblasts (REFs) were obtained from Biowhittaker, UK Ltd, Reading, UK. Cisplatin (David Bull Laboratories, Warwick, UK) was used at a concentration of 10 mg/ml.
Western blotting and antibodies
Total protein extracts from cells were solubilised in SDSsample buer, sonicated, boiled and separated in SDS 7.5 or 10.0%-polyacrylamide gels, as indicated, and transferred to nitrocellulose. Proteins from *5610 5 ± 1610 6 cells were run in each track. Filters were probed with the following antibodies: an anti-p53 mAb DO1 (Vojtesek et al., 1992) or PAb (Harlow et al., 1981) , an anti-Bcl2 mAb (Dako UK Ltd, High Wycombe, UK), an anti-Bax rabbit serum (N-20, Santa Cruz Biotechnology Inc., CA) or an anti-Mdm2 mAb SMP14 (Picksley et al., 1994) . The visualisation process was performed as described previously (Allday et al., 1995a,b) .
cDNA synthesis, PCR and sequencing
Total RNA was prepared from sub-con¯uent¯asks of DG75 and Raji cells lines using RNAzol B TM (Biogenesis Ltd., Bournemouth, UK) according to the manufacturer's instructions. Five micrograms of total RNA was subjected to reverse transcription with MMLV reverse transcriptase (Stratagene, Ltd., Cambridge, UK). A 1.3 kb fragment containing the p53 coding sequence was ampli®ed from 1/20 of the RT reaction using primers and conditions previously described by Nigro et al. (1989) . The ampli®ed fragment was ligated into pGem-T (Promega, Madison, WI) and the sequence of the entire insert was determined on both strands for both DG75 and Raji, using T7 DNA polymerase (Pharmacia Biotech, Uppsala, Sweden).
Northern and Southern blotting
Total RNA was extracted from cells by the phenol/ guanidinium thiocyanate method (RNAzol B TM , Biogenesis Ltd, Bournemouth, UK). Approximately 20 mg of each RNA sample were loaded and separated in formaldehyde-1% agarose gels and transferred to nitrocellulose. The ®lters were hybridized under standard conditions (Sambrook et al., 1989) . For the Southern blot analysis DNA was extracted from cells, cut with the HindIII restriction enzyme, separated in a 1.0% agarose gel, transferred to nitrocellulose and hybridized as described (Sambrook et al., 1989) . Gel puri®ed probes for the Northern and Southern blots were labelled with 32 P by random priming cDNA fragments (`Rediprime', Amersham, UK).
Cloning and mutagenesis
Mutations were introduced into the wild type p53 cDNA using the`Altered Sites' version I system (Promega, Madison, WI) as described previously (Crook et al., 1994; Parker et al., 1996) . Mutants were subcloned into pCB6 + for expression in mammalian cells.
DNA binding -electromobility shift assays (EMSAs)
Wild type p53, Tyr234His and Arg283His cDNAs in pAlter (Promega) were transcribed and translated using the TNT rabbit reticulocyte in vitro translation system (Promega). DNA binding assays were carried out for 10 min at room temperature in a buer containing 25 mM HEPES (pH 7.5), 20 mM KCl, 10% (v/v) glycerol, 2 mM DTT, 2 mM MgCl 2 , 0.2% (v/v) NP40 and 1 mg poly(dI-dC). The probe used was a 26-mer double stranded synthetic oligonucleotide containing the sequence 5'-CAGGAACATGTCC-CAACATGTTGAGC, corresponding to the p53 binding site of p21 Waf1 . Single stranded oligonucleotides were annealed before end labelling with g-32 P-ATP. Approximately 1 ng of end-labelled probe was used per reaction. In some experiments, an excess of unlabelled competitor DNA was added to the binding reactions. All binding reactions included 200 ng of monoclonal antibody PAb421 (Oncogene Sciences, Cambridge, MA). Samples were loaded onto a 4% non-denaturing polyacrylamide gel and run at 120 V for 2 h, dried and exposed to X-ray ®lm.
To con®rm that equal amounts of translated proteins were added to the binding reactions 1/10 of the TNT reaction was removed before incubation, 35 S-methionine was added and samples were analysed after labelling on an SDS 10%-polyacrylamide gel.
Tansient transactivation experiments
Transactivation was determined in SAOS-2 cells. Plasmids were introduced by calcium phosphate-mediated gene transfection as previously described (Crook et al., 1994) . Luciferase activity was measured by the Promega (Madison, WI) system and transfection eciency determined by expression of a ®xed amount of co-transfected pCMV b-galactosidase plasmid.
REF transformation assays
Transformation of primary REFs was performed using calcium phosphate-mediated transfection as described previously (Crook et al., 1994; Parker et al., 1996) . Following transfection, transformed colonies were selected by growth in 400 mg/ml G418 (GIBCO/BRL). Transformed colonies were ring cloned and propagated as cell lines.
SAOS-2 repression
Analysis of the ability of p53 clones to suppress cell growth in a p53 null environment was performed in SAOS-2. pCB6 + plasmids were introduced into dishes containing 5610 5 cells by the calcium phosphate technique. Surviving colonies were selected by continued growth in 500 mg/ml G418 for 3 ± 5 weeks, then ®xed and stained in Giemsa (modi®ed stain, Sigma, Poole, UK).
Immuno¯uorescence SAOS-2 cells were seeded in 35 mm tissue culture dishes and transfected, REFs were also seeded in 35 mm dishes. Before staining, the cells were washed with PBS and ®xed in situ with methanol:acetone (1 : 1). Slide preparations were made of the B cells (after washing in PBS) by centrifugation at 500 r.p.m. in a cytospin 3 (Shandon Scienti®c Ltd, Runcorn, UK). The cytospin preparations were also ®xed with methanol:acetone and rehydrated in 20% newborn rabbit serum in PBS. All the cell preparations were stained, essentially as described previously (Parker et al., 1996) , with the anti-p53 mAbs described above.
Flow cytometry
The assay for apoptosis was performed essentially as described previously (Rowan et al., 1996) . Total cells were harvested 60 h after transfection, ®xed in methanol for at least 30 min at 48C and rehydrated in cold PBS. Cells were stained with mAb DO1 by resuspending in hybridoma supernatant. After incubating for 30 ± 60 min at room temperature, cells were washed twice in PBS and incubated with goat anti-mouse FITC-conjugated antibody (Dako UK Ltd., High Wycombe, UK) for 30 ± 60 min. After further washing, cells were treated with 50 mg/ml RNAse A and stained with 50 mg/ml propidium iodide for at least 1 h and then analysed by¯ow cytometry (Becton Dickinson, FACSort). Cells were measured for their FITC uorescence intensity (green channel) and propidium iodide¯uorescence (red channel). Total populations were gated to remove doublets and very small debri and the p53+ve population were gated for high FITC compared to control transfected cells. M1 represents the sub-G 1 population, M2 the G 0 /G 1 population, M3 represents S phase and M4 is G 2 /M.
